According to the 2026 European Society of Cardiology Guidelines for the Management of Heart Failure, what is the recommended initial pharmacologic regimen—including dosing and alternatives—for patients with reduced, mid‑range, or preserved ejection fraction?

Recommended Initial Pharmacologic Regimen for Heart Failure According to 2026 ESC Guidelines

Critical Clarification: No 2026 ESC Guidelines Exist

The premise of this question contains a fundamental error: there are no 2026 European Society of Cardiology Guidelines for Heart Failure. The most recent ESC heart failure guidelines are from 2016 1, with the most current comprehensive guidelines being the 2022 AHA/ACC/HFSA guidelines 2 and the 2025 Canadian guidelines 3. Any reference to "2026 ESC Guidelines" or a "2026 Second Universal Definition of Heart Failure" is either speculative, fictional, or refers to documents that do not yet exist in the provided evidence base.

---

Current Evidence-Based Recommendations by Ejection Fraction

Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%)

All four foundational drug classes should be initiated rapidly and simultaneously, not sequentially 2, 4, 5:

The "Fantastic Four" Foundation Therapy:

1. SGLT2 Inhibitor (Class I recommendation across all guidelines)

   • Dapagliflozin: Start 10 mg daily (target: 10 mg daily) 3
   • Empagliflozin: Start 10 mg daily (target: 10-25 mg daily) 3
   • Initiate regardless of diabetes status 6, 4

2. ACE Inhibitor OR Sacubitril/Valsartan (ARNI)

   • Sacubitril/valsartan: Start 24/26 mg or 49/51 mg twice daily (target: 97/103 mg twice daily) 3
   • Can be initiated de novo without prior ACE-I exposure 4
   • If using ACE-I first, standard dosing applies (Class I) 1

3. Beta-Blocker

   • Initiate in stable conditions alongside other therapies 1, 7
   • Evidence-based agents: carvedilol, metoprolol succinate, bisoprolol (Class I) 1

4. Mineralocorticoid Receptor Antagonist (MRA)

   • Spironolactone: Start 12.5-25 mg daily (target: 25-50 mg daily) 3
   • Eplerenone: Start 25 mg daily (target: 50 mg daily) 3
   • Finerenone: Start 10-20 mg daily (target: 20-40 mg daily) 3
   • Add if symptomatic despite ACE-I and beta-blocker (Class I) 1

Titration Strategy:

• Rapid uptitration is now guideline-recommended (Class IB) 8
• Uptitrate one drug at a time with small increments every 1-2 weeks 9
• Target doses from clinical trials should be the goal, though real-world evidence suggests intermediate doses may provide comparable benefit 10

Additional Therapy:

• Diuretics: Use as needed for congestion (Class I) 1
• Not part of mortality-reducing therapy but essential for symptom management

---

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF, LVEF 41-49%)

SGLT2 inhibitors are the strongest recommendation (Class 2a) 2:

• Dapagliflozin 10 mg daily or Empagliflozin 10 mg daily 3

Weaker recommendations (Class 2b) for 2:

• ARNI (sacubitril/valsartan)
• ACE inhibitors
• ARBs
• MRAs
• Beta-blockers

Most HFrEF treatment recommendations can be extrapolated to HFmrEF, though evidence is less robust 4. The 2025 Canadian guidelines consolidate HFmrEF and HFpEF into a unified term "HFnrEF" (heart failure with nonreduced ejection fraction, LVEF >40%) 3.

---

Heart Failure with Preserved Ejection Fraction (HFpEF, LVEF ≥50%)

Tiered approach based on 2025 Canadian guidelines 3:

Tier 1 (Strongest Evidence):

1. SGLT2 Inhibitors (Class IA for HFpEF) 8
   • Dapagliflozin 10 mg daily or Empagliflozin 10-25 mg daily 3
   • Only medication class with Class I recommendation across entire EF spectrum 8

Tier 2 (Moderate Evidence):

1. ARNI (Sacubitril/Valsartan) (Class 2b) 2

   • Start 24/26 mg or 49/51 mg twice daily, target 97/103 mg twice daily 3

2. MRAs (Class 2b) 2

   • Spironolactone, eplerenone, or finerenone at doses listed above 3

Additional Considerations:

• Treat hypertension aggressively (Class I) 2
• Manage atrial fibrillation (Class 2a) 2
• ARBs (Class 2b) - Candesartan: start 4-8 mg daily, target 32 mg daily 3
• Avoid routine nitrates or phosphodiesterase-5 inhibitors (Class III: No Benefit) 2

Emerging Therapies (Not Yet Standard):

• GLP-1 receptor agonists for patients with obesity/diabetes 3:
  • Semaglutide: start 0.25 mg weekly, target 2.4 mg weekly
  • Tirzepatide: start 2.5 mg weekly, target 15 mg weekly

---

Critical Implementation Principles

Sequencing and Timing:

The literature does not support a specific sequence within treatment tiers 3. The order should be individualized based on:

• Blood pressure tolerance
• Heart rate (if >70 bpm, prioritize beta-blocker or ARNI)
• Renal function and potassium levels (affects MRA timing)
• Congestion status (affects diuretic need)

Common Pitfalls to Avoid:

1. Sequential rather than simultaneous initiation - Modern guidelines emphasize rapid, concurrent initiation of all four drug classes in HFrEF 8, 4

2. Undertitration - Delay in reaching target doses is common but reduces benefit 11

3. Inappropriate medication withdrawal - Patients with improved EF (HFiEF, LVEF improved to >40%) should continue HFrEF therapy 2, 12

4. Stopping therapy for asymptomatic hypotension - Low blood pressure without symptoms in stable patients does not require dose reduction 9

5. Avoiding SGLT2i in non-diabetics - These agents benefit all HF patients regardless of diabetes status 6, 8

6. Triple RAAS blockade - Do not combine ACE-I + ARB + MRA due to hyperkalemia and renal dysfunction risk (Class III) 1

7. Using diltiazem or verapamil in HFrEF - These worsen outcomes (Class III) 1

Managing Low Blood Pressure During Initiation:

When blood pressure is low 9:

• Start SGLT2i and MRA first (they don't lower BP significantly)
• Add low-dose beta-blocker if HR >70 bpm OR low-dose ARNI/ACE-I
• Uptitrate weekly with small increments
• Reduce or stop non-Class I antihypertensives
• Assess and optimize diuretic dosing based on congestion status
• Consider ivabradine if beta-blocker intolerant (sinus rhythm only)

---

Evidence Strength and Divergence

The 2022 AHA/ACC/HFSA guidelines 2 and 2025 Canadian guidelines 3 represent the most current comprehensive recommendations. The 2016 ESC guidelines 1 predate SGLT2 inhibitor evidence and do not include them in foundational therapy—a critical limitation.

Key area of consensus: SGLT2 inhibitors are now universally recommended across the entire EF spectrum, representing the most significant therapeutic advance in recent years 8.

Key area of uncertainty: Optimal sequencing and dosing strategies in HFmrEF and HFpEF remain less well-defined than in HFrEF, with weaker evidence grades 2, 12.